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An outbreak of human immunodeficiency virus (HIV) among people who inject drugs in Glasgow, Scotland started in 2014. We 
describe 156 cases over 5 years and evaluate the impact of clinical interventions using virological and phylogenetic analysis. We 
established (1) HIV services within homeless health facilities, including outreach nurses, and (2) antiretroviral therapy (ART) via 
community pharmacies. Implementation of the new model reduced time to ART initiation from 264 to 23 days and increased com-
munity viral load suppression rates to 86%. Phylogenetic analysis demonstrated that 2019 diagnoses were concentrated within a 
single network. Traditional HIV care models require adaptation for this highly complex population.
Keywords.  antiretroviral therapy; ART; HIV; outbreak; PWID.
Large-scale outbreaks of human immunodeficiency virus (HIV) 
among people who inject drugs (PWID) have been reported in 
Europe and the United States in recent years [1]. These out-
breaks have been associated with homelessness, economic 
recession, stimulant injecting, suboptimal drug treatment cov-
erage, and injecting equipment provision (IEP). Response to 
these outbreaks has been focused on improving harm reduc-
tion services, such as engagement in opioid agonist therapy 
(OAT), enhanced IEP, and increasing HIV awareness alongside 
antiretroviral therapy (ART) for those diagnosed [1]. Although 
there have been HIV outbreaks among PWID in Scotland in 
the 1980s [2], the most recent was in 1993, with 14 cases identi-
fied [3]. Before 2014, there were between 15 and 20 PWID diag-
nosed with HIV each year in Scotland [4], approximately 10 per 
year in the NHS Greater Glasgow and Clyde Health Board Area 
(hereafter “Glasgow”). In Scotland, free IEP saw over 4.4 mil-
lion needles and syringes distributed in 2016/2017 [5]. Free-to-
access services also provide specialist drug treatment, including 
OAT, with almost 12 000 individuals presenting for assessment 
in 2016/2017 nationally [6]. Low HIV incidence among PWID 
in Scotland was attributed to comprehensive IEP and OAT 
coverage over the last 30  years [7]. Despite this, since 2014, 
Glasgow has experienced a significant rise in HIV diagnoses 
among PWID, closely linked to Glasgow City center. Recent 
epidemiological studies demonstrated that HIV prevalence has 
increased from 1.1% in 2011–2012 to 10.8% in 2017–2018 in 
this population in Glasgow City center. This is associated with 
homelessness, incarceration, injecting cocaine [7], and injecting 
in outdoor locations or “public places” [8], and it represents 
the largest HIV outbreak among this population in the United 
Kingdom (UK) for over 30 years.
Traditionally, HIV care in Glasgow was delivered via a cen-
tralized hospital-based outpatient service, with the exception of 
the blood-borne virus (BBV) prison in-reach service. All pa-
tients had to travel to 1 main hospital located in the west of the 
city, approximately 4 miles from Glasgow City center, to receive 
HIV care. It is recognized that PWID are less likely to remain 
engaged in HIV care and on ART than other cohorts [9]. Before 
2015, among PWID with HIV in Glasgow, nonattendance levels 
at this clinic were high and ART adherence was poor, evidenced 
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by patients not returning to the clinic for repeat ART prescrip-
tions and not achieving viral suppression. Antiretroviral therapy 
was available directly from the hospital or via a home delivery 
service, the latter requiring a stable address and telephone con-
tact. In people whose accommodation is in flux, receiving and 
storing medications is a challenge. Stigma associated with HIV 
infection is commonly expressed in this group even among 
their peers. The challenges in providing high-quality, holistic 
HIV care in this population required a paradigm shift in our 
local HIV care model and approach.
Furthermore, there was an awareness that HIV testing rates 
in drug treatment services, emergency departments, prisons, 
and IEP sites were low. Estimates from public health surveil-
lance suggest that rates before the outbreak were approximately 
30% tested in the last 12 months [10]. An Incident Management 
Team was convened in early 2015 by the public health depart-
ment, and a broad range of strategies were used to address the 
outbreak.
AIM
Public health and clinical responses were initiated to con-
trol this HIV epidemic among PWID in Glasgow. This study 
will describe the clinical response, named Glasgow Enhanced 
Care HIV Outreach (GECHO). We aim to (1) describe the 
sociodemographic characteristics of PWID diagnosed with 
HIV in Glasgow between June 1, 2014 and June 30, 2019, (2) 
describe the clinical interventions implemented in response to 
the HIV outbreak among PWID in Glasgow, and (3) assess the 
impact of the clinical interventions implemented, using clinical 
outcome markers and phylogenetic analysis.
METHODS
Setting
In February 2015, the West of Scotland Specialist Virology Centre 
(WoSSVC) in Glasgow reported to the Public Health Protection 
Unit that an unusually high number of HIV diagnoses had been 
made, via dry blood spot tests sent from drug treatment services 
in the city, in the latter part of 2014 and early 2015. Between June 
1, 2014 and June 30, 2019, 156 people were diagnosed with HIV 
and were identified as part of the Glasgow outbreak. Injecting 
drug use, or sexual contact with someone known to inject drugs, 
were identified as the main risk factors for HIV acquisition. 
Diagnoses over these years were made through the promotion 
of regular (3 monthly) testing for all those attending drug treat-
ment services for OAT and through extensive contact tracing of 
those diagnosed. Phylogenetic analysis demonstrated that this 
strain of subtype C virus, with primary nonnucleoside reverse-
transcriptase inhibitor (NNRTI) mutations E138A and V179E, 
had been transmitted recently and rapidly among Scottish PWID 
but had not yet spread anywhere else in the UK [11]. The char-
acteristics of PWID in Glasgow have been previously described 
[7, 10] with HIV uninfected PWID being predominantly male 
and reporting high levels of heroin and cocaine use, despite the 
majority being prescribed OAT, a marker for engagement with 
specialist drug treatment services.
INTERVENTIONS AND TIMELINE
Education and Awareness
Education and awareness-raising initiatives were immediately 
developed with input from the target population of people 
currently injecting drugs in the city. This included the fol-
lowing steps. (1) Posters were displayed in areas frequented by 
the target population, such as homeless accommodations and 
pharmacies to raise awareness. (2) Leaflets or postcards were 
shared with the target population through third-sector organi-
zations (nongovernmental organizations), the police, and NHS 
services. (3) Various communications and BBV training were 
provided to third-sector organizations, prison healthcare staff, 
and other NHS services who would come into contact with the 
target population. (4) Communications with the general public 
were provided through media release.
HUMAN IMMUNODEFICIENCY VIRUS SERVICE 
DELIVERY RESPONSE TO THE OUTBREAK
It was acknowledged that the affected population struggled to 
engage in HIV care when delivered through a hospital model 
due to social and psychological difficulties. A  different ap-
proach to address ongoing HIV viremia would benefit individ-
uals and crucially would reduce onward transmission.
Homeless health services in Glasgow are based in 1 location 
in the city center and encompass specialist drug treatment serv-
ices and general practice, with visiting services from a range of 
other healthcare teams. This existing homeless health building 
was geographically close to the target population, and patients 
were familiar with it. An intervention model, GECHO, was de-
veloped that supported a BBV clinical nurse specialist initially, 
and later an HIV consultant led service within this setting. 
Pharmacy services were adapted to enhance ART adherence by 
providing ART alongside OAT, which in the majority of patients 
was delivered daily, supervised by their community pharmacist.
JUNE 2016
 1. PART-TIME NURSE SUPPORT
Funding was provided by the Glasgow health board for a 0.5 
full-time equivalent dedicated clinical nurse specialist (approx-
imately £18 000 GBP per year). Their key role is patient en-
gagement in BBV care and includes liaising with multiagency 
partners such as voluntary organizations and other healthcare 
teams. Outreach work includes locating patients who are street 
homeless, in hostels or temporary accommodation, delivering 
ART, with treatment monitoring (venepuncture) and broader 
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health support, OAT, wound care, other medical issues, general 
support, and advocacy.
 2. COMMUNITY PHARMACY ANTIRETROVIRAL 
THERAPY MODEL
We developed a model in which ART could be dispensed daily 
in any Glasgow community pharmacy with or without OAT, and 
supervised if required. There are 291 pharmacies in Glasgow 
that can provide this service. Therefore, the majority of patients 
can receive their daily dose of ART alongside OAT, supervised 
by the pharmacist, in a community pharmacy, close to their ac-
commodation. This service further allows assessment of ART 
adherence. For those who declined supervised dispensing 
of ART, ART uptake was assessed based on prescription and 
self-report of adherence.
SEPTEMBER 2017
 3. FULL-TIME NURSE AND WEEKLY CONSULTANT 
CLINIC
Additional funding for a further 0.5 full-time equivalent clin-
ical nurse specialist and a 0.2 full-time equivalent dedicated 
consultant time was provided by the Glasgow health board at a 
further cost of approximately £27 000 GBP per year. The con-
sultant time provides comprehensive BBV care as well as sexual 
and reproductive health and specialist infectious diseases 
management.
DATA SOURCES AND COLLATION
We retrospectively analyzed data collected as part of routine 
care including social, clinical, and virological information 
from multiple sources (Supplementary Table 1). All individuals 
in Scotland can be uniquely identified via their Community 
Health Index number, which is used as the main identifier for 
each of these data sources. Data were collected until June 30, 
2019 and anonymized for analysis. Date of death or transfer of 
care was captured to account for censoring. To estimate viral 
suppression, a community viral load measurement was calcu-
lated, as per the Centers for Disease Control and Prevention 
guidance [12], reporting on the proportion of cases who 
achieved viral suppression (viral load <200 copies/mL) in each 
3-month period (1 quarter). If more than 1 HIV viral load result 
was available in a quarter, the highest result was used. If no HIV 
viral load measurement was available for 1 quarter, the case was 
only considered to be virally suppressed if the measurements 
immediately before and after that quarter were <200 copies/
mL. Cases were included in the cohort from the date of HIV 
diagnosis and censored at date of death or move. Drug-related 
mortality was defined as per the National Records of Scotland 
definition [13].
Where data were available, we compared our cohort to self-
reported HIV uninfected PWID from Glasgow using data from 
the Needle Exchange Surveillance Initiative (N. Palmateer, PhD, 
15 September 2019, written personal communication), a bien-
nial, national, anonymous bio-behavioral study of PWID in 
Scotland.
LABORATORY METHODS
All laboratory testing was carried out at the WoSSVC, Glasgow. 
Samples (venous blood or dried blood spot samples [DBS]) 
were screened for HIV using the Architect HIV Ag/Ab combo 
assay (modified for DBS) (Abbott, Chicago, IL). Additional 
confirmatory testing was performed using an alternative 
fourth-generation assay (VIDAS; Biomérieux, Marcy l’Etoile, 
France) and/or the Geenius HIV1/2 assay (BioRad, Marnes-la-
Coquette, France). Confirmed HIV-positive samples were fur-
ther tested using an in-house HIV avidity assay that determines 
recency of infection (ie, whether infection was likely to have 
been acquired within the last 4 months) [14]. Baseline resist-
ance testing was performed using a Sanger sequencing-based 
method described previously [11]. Human immunodeficiency 
virus viral load testing was performed using the Abbott HIV-1 
real-time PCR assay.
Samples were also screened for hepatitis C virus (HCV) using 
the Abbott Architect Anti-HCV assay (modified for DBS). 
Positive venous samples were tested using the Abbott real-time 
HCV ribonucleic acid assay or the Abbott ARCHITECT HCV 
Ag assay, whereas DBS were tested using an in house real-time 
PCR assay [15].
Genetic Sequencing and Phylogenetic Analysis
As a routine component of clinical care, the WoSSVC sequences 
the pol region of all new HIV diagnoses (HXB2 positions 2253 
to 3549), as described previously [11]. In July 2019, all subtype 
C sequences with both drug-resistant mutations, diagnosed be-
tween mid-2012 up until 30 June 2019, were collated for analysis 
(n  =  151). Non-C subtypes were not included in the phylo-
genetic analysis even if they were diagnosed during this time 
period. We added sequences from the UK HIV Drug Resistance 
Database found in our earlier analysis to be linked to the cur-
rent outbreak (n  =  28) [11]. We ran HIV-TRACE at a range 
of thresholds (0.5%–2%) to identify the lowest threshold that 
would capture most of the epidemiologically defined outbreak 
[16]. Previously, the outbreak had been entirely linked using a 
single-linkage approach at 1%, meaning that each sequence was 
linked to at least 1 other at a genetic distance threshold of 1%, 
but a genetic distance of 2% remains indicative of membership 
in the same transmission chain [17]. At a genetic distance of 2%, 
175 of 179 sequences analyzed were linked. A phylogeny was re-
constructed for the genetically linked outbreak (n = 175), using 
RaxML [18] under a Generable Time Reversible model with 4 
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treedater package, available in R [19], using sample times as tip 
dates.
STATISTICAL ANALYSIS
Comparing the Glasgow outbreak cohort to HIV-negative 
PWID in Glasgow, we conducted Fisher’s tests for associations 
between being HIV positive and sex, age, previous homeless-
ness, or having injected within the 6 months before diagnosis, 
sharing of injection equipment, prescription of OAT, and hep-
atitis C status. The Needle Exchange Surveillance Initiative 
(NESI) data used are aggregate rather than individual-based; 
therefore, we could not test for interactions between predictors. 
The Mann-Whitney U test was used to compare time from HIV 
diagnosis to ART initiation before and after January 1, 2017.
ETHICAL APPROVAL
Advice was sought from the West of Scotland Research Ethics 
Service and there was no requirement for formal ethical review.
RESULTS
Of the 156 new diagnoses of HIV among PWID or sexual con-
tacts of PWID in Glasgow, from June 1, 2014 to June 30, 2019, 
routine viral sequencing showed 1 of 156 to be subtype A1, 
15 of 156 to be subtype B virus, 2 of 156 unknown (elite con-
troller/low viral load), and 138 of 156 (88.5%) subtype C virus 
with identical primary NNRTI mutations (E138A and V179E), 
indicating a common source for the subtype C outbreak.
Table 1 shows sociodemographic characteristics of the HIV 
outbreak cohort, compared with HIV uninfected PWID in 
Glasgow. The Glasgow HIV outbreak cohort compared with 
HIV-negative PWID in Glasgow (NESI participants [10]) were 
more likely to be women (odds ratio [OR]  =  1.63, P  <  .05), 
younger (P <  .01), more likely to have experienced homeless-
ness within the 6 months before diagnosis (OR = 5.2, P < .0001), 
more likely to have injected within the 6 months before diag-
nosis (OR = 2.4, P < .0001), more likely to be injecting cocaine 
and heroin (P < .001), more likely to share injection equipment 
(OR = 21.12, P < .0001), and more likely to be HCV coinfected 
or to have had HCV in the past (P < .001). There was no signif-
icant different in use of OAT.
For those with HIV immunoglobulin (Ig)G avidity >40%, 
indicating infection acquired more than 4 months before di-
agnosis (n  =  101), the mean CD4 count was 442 cells/mm3 
(standard deviation  =  244 cells/mm3). Forty-five percent (45 
of 101)  had a baseline CD4 count <350 cells/mm3, and, of 
those, the mean CD4 percentage count was 25% (standard de-
viation = 10%). Within those, 22% (22 of 101) had a baseline 
CD4 count <200 cells/mm3. Thirty-two percent (7 of 22)  of 
these were diagnosed with acute HIV infection (IgG avidity 
<40% or negative HIV test within preceding 6  months). Of 
the remaining 15 of 22, the mean CD4 percentage count was 
17% (standard deviation = 8%). No patients have had a clin-
ical acquired immune deficiency syndrome (AIDS)-defining 
illness. Eighteen percent (28 of 156)  of the cohort died. Full 
information on cause of death for 2019 is not yet available, 
but those with information available (93%, 26 of 28)  show 
that 50% (14 of 28)  were drug-related deaths, with an addi-
tional 3 of 28 (11%) due to trauma. There have been no known 
AIDS-related deaths.
Human Immunodeficiency Virus Testing
Data from public health surveillance have shown that self-
reported uptake of HIV testing among PWID in Glasgow has 
increased from 30% in 2013–2014 to 50% in 2017–2018 [10].
Antiretroviral Therapy Uptake and Time to Treatment
Those who died or moved away from Glasgow before initiating 
ART (n = 7) were censored from this analysis. Of the remaining 
patients, all 149 have been commenced on ART, although some 
have had intermittent adherence. The numbers of patients 
diagnosed in each year and included in this analysis are as fol-
lows: 2014, 4; 2015, 47; 2016, 31; 2017, 34; 2018, 19; 2019, 14 
(n = 149).
There has been a reduction in the median time from HIV 
diagnosis to starting ART from 264  days in 2015 (interquar-
tile range [IQR], 94–556) to 23  days (IQR, 12–38) in 2019 
(Figure 1). A comparison of time from diagnosis to ART start 
in those diagnosed from June 1, 2014 to December 31, 2016 to 
those diagnosed from January 1, 2017 to June 30, 2019 showed 
a significant reduction in the median time to ART (Mann-
Whitney U test, P < .00001).
Viral Suppression
One hundred forty-nine patients who started ART were in-
cluded in an analysis of viral load measurements, and those 
who moved or died were censored at date of death or move 
(n = 31). The majority of patients were commenced on a com-
bination of an integrase inhibitor with dual nucleoside reverse-
transcriptase inhibitors (NRTIs).
The proportion of patients achieving viral suppression 
(HIV viral load  <200 copies/mL) in each 3-month period 
(quarters) is shown in Figure 2. The mean proportion of the 
cohort achieving viral suppression in each year is as follows: 
2015, 18%; 2016, 35%; 2017, 64%; 2018, 82%; 2019, 86%. 
This represents a statistically significant increase each year 
(χ 2 test, P <  .05), except for the last year, for which data are 
incomplete.
Antiretroviral Therapy via Community Pharmacies
Sixty-one percent (91 of 149) of patients who commenced ART 
in the cohort have ever received ART via community-based 
pharmacy care since June 2016. In June 2018, this proportion 
was 59% (77 of 130), and in June 2017 it was 29% (25 of 84); 
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Table 1. Sociodemographic Characteristics of the HIV Outbreak Cohort Compared With HIV Uninfected PWID in Glasgow
HIV Outbreak Cohort  
(n = 156)
HIV Uninfected PWID  
(n = 780) P Value
Social Characteristics Sex    
 Female 53/156 (34%) 186/780 (24%)  
 Male 103/156 (66%) 590/780 (76%)  
 Unknown 0/156 (0%) 4/780 (1%)  
    <.05
 Age    
 <35 39/156 (25%) 111/780 (14%)  
 35–39 49/156 (31%) 196/780 (25%)  
 40–44 31/156 (20%) 217/780 (28%)  
 45+ 37/156 (24%) 256/780 (33%)  
    <.01
 Homelessness (defined as no tenancy)    
 Yes 100/156 (64%) 198/780 (25%)  
 No 56/156 (36%) 576/780 (74%)  
 Unknown 0/156 (0%) 6/780 (1%)  
    <.0001
In the 6 Months Before HIV Diagnosis
 Incarceration  Not available  
 Yes 54/156 (35%)   
 No 102/156 (65%)   
Risk Behaviors Injecting Drug Use    
 Yes 130/156 (81%) 523/780 (67%)  
 No 26/156 (19%) 251/780 (32%)  
 Unknown 0/156 (0%) 6/780 (1%)  
    <.0001
 Main Drug Injected    
 Cocaine 18/130 (14%) 114/523 (22%)  
 Heroin 51/130 (39%) 366/523 (70%)  
 Heroin and cocaine 61/130 (47%) 15/523 (3%)  
 Other 0/130 (0%) 28/523 (5%)  
    <.001
 Self-Reported Sharing of Needles or Syringes    
 Yes 62/130 (48%) 52/523 (10%)  
 No 26/130 (20%) 465/523 (89%)  
 Unknown 42/130 (32%) 6/523 (1%)  
    <.0001
 Sexual Intercourse  Not available  
 Yes 93/156 (60%)   
 No 55/156 (35%)   
 Unknown 8/156 (5%)   
     
Type of HIV Acquisition Risk Disclosed From Contact Tracing (Some Reported More Than 1 
Type of Risk)
 Not applicable  
 Injecting drug use/shared injecting equipment contacts 97/156 (62%)   
 Sexual contacts 72/156 (46%)   
 Sexual and sharing injecting equipment contacts 40/156 (26%)   
Harm Reduction Prescribed opioid agonist therapy    
 Yes 128/156 (82%) 627/780 (80%)  
 No 28/156 (18%) 147/780 (19%)  
 Unknown 0/156 (0%) 6/780 (1%)  
    .823
Acute Presentations Glasgow acute hospital unscheduled presentations  Not available  
 None 54/156 (34%)   
 1–5 87/156 (56%)   
 6–10 12/156 (8%)   
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increasing over time. Reasons for cessation of ART delivery 
via this method included death, incarceration, patient choice 
to receive via other methods, or intermittently stop ART. In 
addition, transient interruption may occur due to unexpected 
changes in location of accommodation and therefore local com-
munity pharmacy.
Phylogenetic Analysis
We found 175 individuals whose HIV sequences linked at 2% 
genetic distance in HIV-TRACE, including 37 individuals diag-
nosed before June 1, 2014. Inclusion of older sequences im-
proves the resolution of time-measured phylogenies, and so we 
chose to include all genetically linked sequences in our phylo-
genetic analysis. We observed new diagnoses in all 3 subclusters 
observed in our previous analysis [11]. Despite the high number 
of diagnoses in 2019 (n = 14), the majority of these sequences 
(n = 10) were part of a single large cluster, likely representing a 
single social network.
DISCUSSION
Despite comprehensive and free to access IEP and specialist 
drug treatment services, HIV spread rapidly among PWID in 
Glasgow from 2014 onwards with prevalence now exceeding 
10% within this vulnerable city center population [7]. We com-
pared the outbreak cohort with PWID from Glasgow who 
report to be HIV negative to identify predictors for HIV ac-
quisition. This comparator group was current, local, and had 
data available for comparison. Using a case-control analysis, we 
have shown that differences in drug injecting behavior (such 
as sharing injecting equipment), higher levels of homelessness, 
and HCV infection are associated with HIV positivity (Table 1). 
To address the outbreak, parallel interventions including edu-
cation of healthcare workers and third-sector organizations and 
awareness raising among the target population were introduced 
early. Improvements to IEP, including provision of lower dead 




























Year of  HIV diagnosis
2017 2018 2019
0
Figure 1. Time from human immunodeficiency virus (HIV) diagnosis to antiretroviral therapy (ART) initiation, by year of HIV diagnosis. Box and whisker plot showing min-
imum, first quartile, median, third quartile, and maximum time in days.
HIV Outbreak Cohort  
(n = 156)
HIV Uninfected PWID  
(n = 780) P Value
     
BBV Status HIV infection duration (recent infection defined as IgG 
avidity <40%)
 Not applicable  
 Early 53/156 (34%)   
 Chronic 101/156 (65%)   
 Unknown 2/156 (1%)   
 HCV status at diagnosis    
 Ab positive, HCV PCR/Ag negative 58/156 (37) 190/780 (24)  
 Ongoing/active HCV infection 92/156 (59) 268/780 (34)  
 HCV negative (Ab and Ag/PCR) 6/156 (4) 262/780 (34)  
 Unknown 0/156 (0%) 60/780 (8)  
    <.001
Abbreviations: Ab, antibody; Ag, antigen; BBV, blood-borne virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; PCR, polymerase chain reaction; PWID, 
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weekend, were added to the existing harm-reduction arma-
mentarium. Planned developments within the drug treatment 
services were also implemented, as recommended by a health 
needs assessment [20]. Despite a focus on harm reduction and 
comprehensive treatment from drug recovery services (OAT 
programs), injecting and sharing of drug injecting equipment 
persisted. This is partly related to the rapid rise in cocaine use 
and the limited interventions to manage this. Given its short 
half-life there is an increase injecting frequency and, in turn, 
blood-borne virus transmission risk through reduced likeli-
hood of using clean equipment at each injection [21, 22]. Drug 
treatment services also reviewed optimizing OAT dosing, and 
a heroin-assisted treatment program opened in Glasgow in 
October 2019. Furthermore, risk-taking behavior can be influ-
enced by structural factors including environmental conditions 
such as homelessness [23, 24].
A large number of the cohort reported sexual risks for HIV 
acquisition, and, in Scotland, HIV pre-exposure prophylaxis 
(PrEP) is provided free of charge from sexual health services 
for those at risk of HIV via sexual risk [25]. The HIV-negative 
sexual partners of PWID are generally from similarly multi-
disadvantaged backgrounds and face barriers to accessing 
HIV prevention services [26]. The PrEP delivery among 
PWID has required modification of this service, and early 
evaluation suggests acceptability among the small group en-
gaged. In Glasgow, at time of writing, of 20  “at risk” PWID 
offered HIV PrEP, 75% had commenced it (R. Metcalfe, FRCP, 
25 September 2019, written personal communication).
A centralized, hospital-based service was developed many 
years ago to support HIV care in a holistic way through a 
colocated, multidisciplinary team. This group was already dis-
advantaged, and the need to travel without financial means and 
set appointment times that offered little flexibility proved to 
be significant barriers to engagement. To address this, a spe-
cific HIV clinic was set up within the homeless health services 
building, but it was poorly utilized in this location reportedly 
due to HIV-related stigma. Responding to this feedback, the 
HIV clinic was changed to a general BBV clinic, which was 
more acceptable. This clinic now has the ability to manage and 
treat all BBVs, provide comprehensive sexual and reproductive 
healthcare, and support outpatient management of physical 
health conditions including serious soft tissue infections.
In modeling studies, HIV treatment as prevention (TasP) 
has been shown to be economically beneficial [27]. In Scotland, 
as per national guidelines, ART is started as soon as possible, 
for individual health benefit and TasP, and is free of charge. 
However, it is recognized that concerns about drug interactions 
(including with nonprescribed “street drugs”), perceived or 
actual poor engagement in care, poor adherence, and the po-
tential development of antiretroviral resistance historically has 
led to reluctance to prescribe ART to those with ongoing drug 
use [9]. The vast majority of this population were infected with 
a primary resistant subtype C HIV virus, and there was con-
cern about progressive resistance given the likelihood of poor 
adherence.
Before July 2016, ART could only be obtained via the hospital 
pharmacy or via a home delivery service. We developed a model 
in which ART could be dispensed daily in any Glasgow com-
munity pharmacy with or without OAT, supervised if required. 
Avoidance of drug interactions was a key concern given high 
levels of street drug use and other comedications, due to high 
levels of physical and mental comorbidities. Therefore, protease 
inhibitors were generally avoided, in addition to NNRTIs, given 
the primary resistance mutations identified. The combination of 
a favorable drug interaction profile, high genetic barrier to re-
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Figure 2. Line graph representing the proportion of patients in the human immunodeficiency virus (HIV) outbreak cohort achieving viral suppression (HIV viral load <200 
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the integrase inhibitor class a first-line choice for this cohort. In 
2015, the UK treatment guidelines had twice-daily raltegravir as 
the integrase of choice, and dolutegravir was approved for use in 
Scotland (in 2014). With the benefits of once-daily dosing, the 
majority of patients have been prescribed a dolutegravir-based 
regimen, alongside dual NRTIs.
There are high rates of intermittently poor adherence to ART 
despite GECHO and focused counseling around adherence. 
This cohort move accommodation and community pharmacy 
location frequently. Interruptions in OAT can interfere with 
daily pharmacy visits. The ART-dispensing model has the flex-
ibility to move between community pharmacies as well as hos-
pital pharmacies as their needs change.
This requires significant input from hospital HIV pharmacy 
services who oversee the individual prescription and ensure 
ART continuation in those circumstances. A  temporary pre-
scription can be delivered to the patient by the outreach nurse 
until a stable prescribing situation can be regained. Support 
from third-sector organizations can help in locating the patients 
rapidly when they fall out of care, and these links with a mul-
titude of healthcare providers are essential. The rate at which 
ART is commenced has improved due a multiplicity of factors, 
but the team aims to start patients on ART now on the same day 
as a new diagnosis result is returned (Figure 1). No HIV-related 
deaths have occurred, but there are high rates of unscheduled 
hospital care due to significant comorbidities, and mortality 
within the cohort is high [28].
It is challenging to justify the financial input required to 
achieve treatment goals where a service already exists. However, 
the data collected and analyzed in Figures 1 and 2 have shown 
that GECHO, as a response to this health inequality, can achieve 
results comparable with other HIV-positive cohorts. These met-
rics can also be used as an indicator for reduction in estimated 
community viral load and used to evaluate outbreak interven-
tions such as TasP. The success of GECHO is further supported 
by phylogenetic analysis, highlighting that the majority of in-
fections in 2019 (10 of 14)  were concentrated within a single 
cluster, in contrast to widespread transmission between 2014 
and 2018 (Figure 3). Transmission has been interrupted in all 
but a single network. Phylogenetic analysis in real-time has, 
alongside partner notification, informed the public health re-
sponse, allowing targeting of resources to key groups.
However, the development of the GECHO model of clinical 
care has been a significant challenge, especially in the current 
UK environment of austerity. In this group, it was clear that 
engagement in care required relationship building, between 
healthcare worker and patient, but also between existing serv-
ices that do not traditionally work closely together, eg, hospital 
clinicians and nongovernmental organizations. There are no 
authoritative guidelines or local health economic analyses to in-
form a healthcare team and their sponsors on the required sup-
port and funding to clinically manage an HIV outbreak among 
PWID. Upfront investment of significant HIV specialist clinical 
time for a relatively small number of patients from a group with 
poor self-esteem needs continued advocacy. The recent out-
break in Athens [29] demonstrated the urgency with which a 
care model should be implemented to stem onward transmis-
sion. We have demonstrated that by adapting traditional models 
of care, successful clinical outcomes and public health interven-
tion, including TasP, are achievable with relatively little invest-
ment in staff costs. However, the timelines suggest that a more 
urgent response may have improved outcomes at an earlier date.
This outbreak occurred in a setting that provided a high 
standard of drug recovery service and high level of IEP for 
PWIDs, but it lacked in comprehensive BBV testing and moni-
toring of HIV incidence rates. The experience in Glasgow 
should highlight to public health teams with a similar demo-
graphic to be vigilant to an HIV outbreak despite good harm 
reduction services. Rigorous testing programs are required.
Limitations
This study is an observational retrospective cohort study, and 
there are limitations to the data collection, which was reliant 
on accurate recording by healthcare workers and accurate 
self-reporting from patients and therefore potentially subject 
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available every 3  months due to patient disengagement. For 
those with chronic infection, we are unable to determine when 
acquisition occurred, and so the risk factors described may not 
have been present at the time of HIV infection. Many variables 
may have impacted on virological suppression and engagement 
in care that cannot be easily measured. The use of community 
viral load was chosen as the most reliable estimate of viral load 
for the cohort, including those not in care, but it has limitations 
in that it does not account for variability of HIV viral load be-
tween measurements and does not take into account the viral 
load measurements of those who are undiagnosed [12].
Because the cohort can move between community-dispensed 
ART and hospital dispensed, we are unable to compare viral 
suppression levels in the 2 groups. Using the NESI cohort for 
the case-control analysis may not be considered the best com-
parison group because the participants’ inclusion in NESI may 
indicate that they are more likely to be using needle exchange 
than the members of the outbreak cohort. However, mem-
bers of the outbreak were also using needle exchange facilities, 
and this convenience sample was the best group available for 
comparison.
CONCLUSIONS
Responding to HIV outbreaks in a PWID population re-
quires an urgent clinical response team in addition to wider 
public health interventions. Advocacy for rapid investment in 
a GECHO model of care would be easier with a more detailed 
health economic analysis and supporting guideline or policy 
document from a recognized body. The adaptation of clinical 
services is vital to improve health outcomes and reduce onward 
transmission when managing an HIV epidemic in this highly 
complex and multiply disadvantaged group. We believe that this 
model can be replicated in other locations, but to deliver good 
clinical and virological HIV outcomes, appropriate and rapid 
investment, especially in staff costs, is required.
Supplementary Data
Supplementary materials are available at The Journal of 
Infectious Diseases online. Consisting of data provided by 
the authors to benefit the reader, the posted materials are 
not copyedited and are the sole responsibility of the au-
thors, so questions or comments should be addressed to the 
corresponding author.
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